Detalles de la búsqueda
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37407001
2.
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Blood
; 142(1): 62-72, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36796019
3.
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Br J Cancer
; 124(8): 1388-1397, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33531690
4.
Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies.
Oncologist
; 26(9): e1538-e1547, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037286
5.
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
Liver Int
; 41(3): 598-607, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33188713
6.
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Liver Int
; 41(11): 2759-2767, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34173317
7.
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascites.
Hepatol Res
; 51(6): 715-721, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743189
8.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(2): 282-296, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30665869
9.
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.
Liver Int
; 39(12): 2214-2229, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31436873
10.
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Br J Cancer
; 119(1): 19-26, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29808014
11.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 16(7): 859-70, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26095784
12.
Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
J Patient Rep Outcomes
; 8(1): 8, 2024 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252198
13.
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 57-67, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335022
14.
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.
Leuk Lymphoma
; 64(5): 1005-1016, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36987650
15.
Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model-Informed Drug Development Paradigm.
Clin Pharmacol Ther
; 114(1): 77-87, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37087634
16.
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study.
J Gastric Cancer
; 23(2): 289-302, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37129153
17.
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
J Clin Oncol
; 41(24): 3988-3997, 2023 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37192437
18.
Sec61ß controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Mol Pharmacol
; 82(3): 510-20, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22710939
19.
Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study.
Adv Hematol
; 2022: 8262787, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36620778
20.
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
Clin Cancer Res
; 28(11): 2297-2305, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247922